Pomerantz Law Firm Investigates Compass Therapeutics for Potential Securities Fraud
Pomerantz LLP is investigating Compass Therapeutics (NASDAQ: CMPX) for potential securities fraud following a significant drop in its stock price after a clinical trial missed a key endpoint. The firm is seeking investors to join a class action.
Tickers: $CMPX
Topics: class_action clinical_trial_results securities_fraud stock_price_drop